X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (120) 120
humans (113) 113
male (69) 69
female (68) 68
hematology (68) 68
multiple myeloma (66) 66
aged (65) 65
middle aged (59) 59
multiple myeloma - drug therapy (57) 57
oncology (47) 47
treatment outcome (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
bortezomib (39) 39
adult (36) 36
stem-cell transplantation (32) 32
thalidomide (31) 31
dexamethasone (29) 29
disease-free survival (29) 29
thalidomide - administration & dosage (28) 28
therapy (28) 28
multiple myeloma - mortality (27) 27
aged, 80 and over (26) 26
chemotherapy (25) 25
lenalidomide (23) 23
survival (21) 21
melphalan - administration & dosage (20) 20
multiple myeloma - therapy (20) 20
retrospective studies (20) 20
analysis (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
transplantation (19) 19
cancer (18) 18
care and treatment (18) 18
dexamethasone - administration & dosage (17) 17
survival analysis (17) 17
abridged index medicus (16) 16
elderly-patients (16) 16
hematology, oncology and palliative medicine (16) 16
multiple myeloma - pathology (15) 15
prognosis (15) 15
risk factors (15) 15
thalidomide - adverse effects (15) 15
thalidomide - analogs & derivatives (15) 15
melphalan (14) 14
survival rate (14) 14
autologous transplantation (13) 13
thalidomide - therapeutic use (13) 13
antineoplastic agents - therapeutic use (12) 12
follow-up studies (12) 12
prospective studies (12) 12
stem cells (12) 12
transplantation, autologous (12) 12
adolescent (11) 11
combination (11) 11
kaplan-meier estimate (11) 11
leukemia (11) 11
medical research (11) 11
prednisone (11) 11
clinical trials (10) 10
diagnosis (10) 10
initial treatment (10) 10
multiple myeloma - diagnosis (10) 10
multiple-myeloma (10) 10
pegylated liposomal doxorubicin (10) 10
prednisone - administration & dosage (10) 10
stem cell transplantation (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
boronic acids - administration & dosage (9) 9
cyclophosphamide (9) 9
doxorubicin - administration & dosage (9) 9
hematopoietic stem cell transplantation (9) 9
high-dose melphalan (9) 9
lenalidomide plus dexamethasone (9) 9
maintenance (9) 9
patients (9) 9
pyrazines - administration & dosage (9) 9
randomized controlled-trial (9) 9
recurrence (9) 9
remission induction (9) 9
clinical trials as topic (8) 8
disease progression (8) 8
maintenance therapy (8) 8
medicine & public health (8) 8
medicine, experimental (8) 8
melphalan - adverse effects (8) 8
mortality (8) 8
multiple myeloma - complications (8) 8
pharmacology & pharmacy (8) 8
phase-ii (8) 8
research (8) 8
safety (8) 8
salvage therapy (8) 8
bone marrow (7) 7
bortezomib-melphalan-prednisone (7) 7
carfilzomib (7) 7
complications and side effects (7) 7
doxorubicin - analogs & derivatives (7) 7
drug therapy (7) 7
efficacy (7) 7
elderly (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer | Index Medicus
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2017, Volume 176, Issue 6, pp. 845 - 846
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
Haematologica, ISSN 0390-6078, 04/2010, Volume 95, Issue 4, pp. 644 - 650
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 26, pp. 2863 - 2869
Journal Article